HLB Life Science Co. Ltd (067630) - Total Liabilities

Latest as of September 2025: ₩173.00 Billion KRW ≈ $117.24 Million USD

Based on the latest financial reports, HLB Life Science Co. Ltd (067630) has total liabilities worth ₩173.00 Billion KRW (≈ $117.24 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

HLB Life Science Co. Ltd - Total Liabilities Trend (2012–2024)

This chart illustrates how HLB Life Science Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See HLB Life Science Co. Ltd (067630) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

HLB Life Science Co. Ltd Competitors by Total Liabilities

The table below lists competitors of HLB Life Science Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
P2 Gold Inc V:PGLD	Canada	CA$1.44 Million
SR Bancorp, Inc. Common stock NASDAQ:SRBK	USA	$959.00 Million
Hwashin Precision Engineering Co. Ltd KQ:126640	Korea	₩108.61 Billion
Stomil Sanok SA WAR:SNK	Poland	zł690.68 Million
Soechi Lines Tbk JK:SOCI	Indonesia	Rp203.62 Million
Hardwyn India Limited NSE:HARDWYN	India	Rs756.38 Million
Thessaloniki Water Supply & Sewerage Co S.A AT:EYAPS	Greece	€55.08 Million
Korea Information Certificate Authority Inc KQ:053300	Korea	₩170.54 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down HLB Life Science Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HLB Life Science Co. Ltd (067630) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.93	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.62	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.38	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HLB Life Science Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HLB Life Science Co. Ltd (2012–2024)

The table below shows the annual total liabilities of HLB Life Science Co. Ltd from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩140.19 Billion ≈ $95.01 Million	-27.09%
2023-12-31	₩192.29 Billion ≈ $130.31 Million	+8.60%
2022-12-31	₩177.07 Billion ≈ $119.99 Million	+619.47%
2021-12-31	₩24.61 Billion ≈ $16.68 Million	-38.50%
2020-12-31	₩40.02 Billion ≈ $27.12 Million	-43.73%
2019-12-31	₩71.11 Billion ≈ $48.19 Million	-57.46%
2018-12-31	₩167.17 Billion ≈ $113.29 Million	+261.90%
2017-12-31	₩46.19 Billion ≈ $31.30 Million	-16.00%
2016-12-31	₩54.99 Billion ≈ $37.27 Million	+227.27%
2015-12-31	₩16.80 Billion ≈ $11.39 Million	-15.78%
2014-12-31	₩19.95 Billion ≈ $13.52 Million	-46.35%
2013-12-31	₩37.19 Billion ≈ $25.20 Million	-4.21%
2012-12-31	₩38.83 Billion ≈ $26.31 Million	--

About HLB Life Science Co. Ltd

KQ:067630 Korea Pharmaceuticals

Market Cap

$136.50 Million

₩201.42 Billion KRW

Market Cap Rank

#18086 Global

#802 in Korea

Share Price

₩4300.00

Change (1 day)

+0.70%

52-Week Range

₩3235.00 - ₩5750.00

All Time High

₩23674.87